1 minute read
The new Fellows have been elected to the Academy in recognition of their exceptional contributions to the advancement of biomedical and health science, cutting edge research discoveries, and translating developments into benefits for patients and wider society.
Ian Gilmore is a physicist who has made pioneering advances in high-resolution molecular imaging by mass spectrometry. His innovation of OrbiSIMS technology has had a wide impact across research in biomedicine and novel devices, revolutionising the ability to visualise the distributions of drugs, metabolites and other chemicals in biological tissues with exquisite detail. Now commercialised, OrbiSIMS instruments are being used around the world, giving ground-breaking insights into how neighbouring cells regulate each other’s metabolism, to map metabolic heterogeneity in cancer tumours and next generation biomaterials discovery.
He is the founding director of the National Centre of Excellence in Mass Spectrometry Imaging. Established in 2012, the centre supports industry and academia through one of the largest ranges of imaging capabilities worldwide. He champions the topic of reproducibility and research integrity and is a member of the new UK Committee on Research Integrity.
Professor Gilmore is one of 59 influential biomedical and health scientists to be elected in 2023’s cohort of Fellows and joins 1,400 esteemed researchers who are central to the Academy’s work. This includes providing career support to the next generation of researchers and contributing to the Academy’s influential policy work to improve health in the UK and globally.
JT Janssen, Chief Scientist, NPL said: “I’m delighted that Professor Ian Gilmore’s outstanding contributions to biomedical research have been recognised by the prestigious Academy of Medical Sciences. As the first person from NPL to be elected to the Academy’s Fellowship, Ian continues to be at the forefront of developments in biomedical and health research.”
18 May 2023